Mindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds Post published:April 29, 2021 Post category:Press Release
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC Post published:April 29, 2021 Post category:Press Release
Delix Therapeutics Co-Founder Publishes Groundbreaking Study Demonstrating Therapeutic Potential for a Psychedelic Analog—Without Hallucinogenic Effects Post published:April 28, 2021 Post category:Press Release
Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics Post published:April 28, 2021 Post category:Press Release
PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation Post published:April 28, 2021 Post category:Press Release
COMPASS Pathways launches proposed public offering Post published:April 27, 2021 Post category:Press Release
Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to Develop Multi-Sensory Pods for Clinical Psychedelic Use Post published:April 27, 2021 Post category:Press Release
Red Light Holland and Halo Collective Create Red Light Oregon, Inc. – Forwarding Intentions to Enter Oregon Medicinal Psychedelic Market Post published:April 27, 2021 Post category:Press Release
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury Post published:April 27, 2021 Post category:Press Release
Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands Scientific Advisory Team Post published:April 27, 2021 Post category:Press Release